Published in BMC Infect Dis on April 03, 2012
Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood (2015) 0.84
Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole. Infect Drug Resist (2015) 0.78
Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. Adv Ther (2017) 0.75
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med (2007) 10.40
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med (2007) 7.91
Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis (2003) 7.09
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03
An introduction to Markov modelling for economic evaluation. Pharmacoeconomics (1998) 4.27
Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis (1999) 2.48
Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol (2006) 2.37
European healthcare policies for controlling drug expenditure. Pharmacoeconomics (2003) 1.95
Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol (2007) 1.82
[What is an efficient health technology in Spain?]. Gac Sanit (2002) 1.54
Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer (2002) 1.50
Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. J Natl Compr Canc Netw (2008) 1.46
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer (2006) 1.36
Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics (2006) 1.35
Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis (2004) 1.33
Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ (2010) 1.17
Posaconazole : a review of its use in the prophylaxis of invasive fungal infections. Drugs (2008) 1.02
Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health (2011) 1.01
Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol (2008) 0.97
The First European Conference on Infections in Leukaemia - ECIL1: a current perspective. Eur J Cancer (2008) 0.95
Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother (2005) 0.92
Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Int J Infect Dis (2004) 0.91
Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm (2008) 0.90
Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl Infect Dis (2007) 0.86
Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist (2007) 0.84
Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother (2005) 0.82
Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Pharmacoeconomics (2008) 0.81
Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland. Oncology (2010) 0.81
[Economic evaluation of voriconazole versus amphotericin B in the treatment of invasive aspergilosis]. Farm Hosp (2005) 0.80
Cost-benefit assessment of antifungal prophylaxis with liposomal amphotericin B in neutropenic patients. Onkologie (2007) 0.78
Prophylaxis and treatment of fungal infections associated with haematological malignancies. Int J Antimicrob Agents (2000) 0.78
The clinical and pharmacoeconomic analysis of invasive aspergillosis in adult patients with haematological diseases. Mycoses (2008) 0.77
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (2008) 3.74
Nonmalignant late effects after allogeneic stem cell transplantation. Blood (2003) 2.95
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol (2009) 2.39
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica (2008) 2.32
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood (2002) 2.14
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood (2008) 2.04
[Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia]. Med Clin (Barc) (2012) 2.02
[Meta-analysis on safety and efficacy of liposomal amphotericin B in the empirical treatment of febrile neutropenia]. Med Clin (Barc) (2004) 2.02
Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica (2010) 1.91
Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood (2011) 1.89
Role of depression as a predictor of mortality among cancer patients after stem-cell transplantation. J Clin Oncol (2005) 1.89
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant (2009) 1.87
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood (2013) 1.74
Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy (2010) 1.69
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma (2006) 1.65
Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol (2010) 1.57
Changes of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) after autologous hematopoietic stem cell transplantation in multiple sclerosis. J Neuroimmunol (2004) 1.56
Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res (2006) 1.54
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood (2013) 1.54
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood (2007) 1.53
Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood (2010) 1.52
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood (2012) 1.50
Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease. Arch Dermatol (2008) 1.50
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica (2009) 1.44
Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). Leuk Lymphoma (2013) 1.43
Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon. Haematologica (2002) 1.42
Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol (2002) 1.41
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica (2009) 1.39
Platelet transfusion and thrombotic thrombocytopenic purpura. Transfusion (2002) 1.39
[Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1]. Farm Hosp (2009) 1.38
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica (2013) 1.32
Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica (2003) 1.30
Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant (2006) 1.28
Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica (2003) 1.24
Cord-blood transplantation in patients with leukemia--a real alternative for adults. N Engl J Med (2004) 1.24
The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet (2002) 1.22
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood (2010) 1.20
Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol (2005) 1.15
Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant (2009) 1.14
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol (2009) 1.14
Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica (2008) 1.12
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood (2008) 1.11
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica (2011) 1.09
Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clin Infect Dis (2004) 1.08
Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler (2009) 1.08
Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol (2005) 1.06
Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis (2006) 1.05
Viroporin activity of murine hepatitis virus E protein. FEBS Lett (2005) 1.05
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer (2003) 1.05
Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfus Apher Sci (2010) 1.03
The European LeukemiaNet: achievements and perspectives. Haematologica (2010) 1.02
Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica (2008) 1.01
Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia. Cancer Sci (2009) 1.01
Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol (2006) 0.99
Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant (2010) 0.98
One-unit versus two-unit cord-blood transplantation. N Engl J Med (2015) 0.96
Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion (2002) 0.96
Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol (2004) 0.95
Central nervous system involvement at first relapse in patients with acute myeloid leukemia. Haematologica (2011) 0.95
A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood (2010) 0.95
Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? Thromb Res (2007) 0.94
The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature. Mediterr J Hematol Infect Dis (2011) 0.94
Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies. Haematologica (2009) 0.94
Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clin Transl Oncol (2011) 0.94
Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant (2009) 0.93
Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. J Clin Oncol (2006) 0.93
Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant (2012) 0.92
Drug safety evaluation of defibrotide. Expert Opin Drug Saf (2012) 0.92
The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica (2007) 0.91
Enumeration of cytomegalovirus-specific interferongamma CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. Haematologica (2008) 0.90
Treatment and timing in invasive mould disease. J Antimicrob Chemother (2011) 0.90
Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience. Transplantation (2011) 0.89
Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocytic leukemia. Ann Hematol (2012) 0.89
Case collection study of the safety of AmBisome in association with voriconazole in the treatment of patients with invasive fungal infection. Rev Esp Quimioter (2010) 0.89
Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2010) 0.88
Fungemia due to Candida guilliermondii in a pediatric and adult population during a 12-year period. Diagn Microbiol Infect Dis (2007) 0.88
Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. Lancet Neurol (2005) 0.88
An assessment of the effect of human herpesvirus-6 replication on active cytomegalovirus infection after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2010) 0.87
Clinical factors influencing T-cell receptor excision circle (TRECs) counts following allogeneic stem cell transplantation in adults. Transpl Immunol (2006) 0.87
Fatal immune hemolytic anemia following allogeneic stem cell transplantation: report of 2 cases and review of literature. Transfus Med Rev (2013) 0.87